SRINAGAR: In a landmark achievement for India’s pharmaceutical sector, the country has introduced its first indigenous antibiotic, Nafithromycin, designed to combat drug-resistant infections. Developed by Wockhardt with support from the Biotechnology Industry Research Assistance Council (BIRAC), a unit of the Department of Biotechnology, Nafithromycin is marketed under the trade name “Miqnaf.” This novel antibiotic specifically targets Community-Acquired Bacterial Pneumonia (CABP), a severe illness caused by drug-resistant bacteria that disproportionately affects vulnerable populations, including children, the elderly, and immunocompromised individuals.
Nafithromycin, the government informed Rajya Sabha, offers a groundbreaking three-day treatment regimen, which is ten times more effective than current options and provides a safer, faster, and more tolerable solution for patients. Its efficacy stands out as it targets both typical and atypical pathogens, offering a potent solution where no new antibiotic in this class has been developed worldwide for over three decades. Beyond its efficacy, Nafithromycin boasts superior safety and tolerability, with minimal gastrointestinal side effects, no significant drug interactions, and remains unaffected by food, making it a versatile option for patients.
The development of Nafithromycin represents 14 years of dedicated research and an investment of Rs 500 crores, with clinical trials spanning the U.S., Europe, and India. Supported by BIRAC under its Biotechnology Industry Partnership Program (BIPP), the initiative showcases the power of public-private collaboration in advancing healthcare innovation. The drug is now awaiting final approval from the Central Drugs Standard Control Organization (CDSCO) for manufacturing and public use, marking a major leap forward in India’s fight against Antimicrobial Resistance (AMR).
Union Minister Dr Jitendra Singh, during the soft launch of Nafithromycin, highlighted the significance of this achievement, stating that it reaffirms India’s commitment to addressing AMR and improving public health, while positioning the nation as a global leader in biotechnology innovation. He emphasized the importance of innovation and collaboration in tackling AMR, calling it a global crisis that prolongs illnesses and raises healthcare costs. Dr. Singh also urged the scientific community to leverage this momentum to drive further advancements in diagnostics, AMR surveillance, and new antibiotic research.
The launch of Nafithromycin signals India’s determination to combat AMR and contribute meaningfully to global health. As World AMR Awareness Week shines a spotlight on the global challenge of antimicrobial resistance, stakeholders from the government, pharmaceutical industry, and research institutions are called upon to work collectively in combating this threat. The success of Nafithromycin is a testament to India’s growing capability to develop homegrown solutions for pressing healthcare challenges
